benzazepines

Summary

Summary: Compounds with BENZENE fused to AZEPINES.

Top Publications

  1. ncbi Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling
    Gerard J O'Sullivan
    Molecular and Cellular Therapeutics and RCSI Research Institute, Royal College of Surgeons in Ireland, Dublin 2, Ireland
    Neuropharmacology 54:1051-61. 2008
  2. ncbi Varenicline reduces alcohol self-administration in heavy-drinking smokers
    Sherry A McKee
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
    Biol Psychiatry 66:185-90. 2009
  3. ncbi Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking
    Pia Steensland
    Ernest Gallo Clinic and Research Center, University of California, San Francisco, 5858 Horton Street, Suite 200, Emeryville, CA 94608, USA
    Proc Natl Acad Sci U S A 104:12518-23. 2007
  4. ncbi Multicenter, placebo-controlled trial of lorcaserin for weight management
    Steven R Smith
    Translational Research Institute for Metabolism and Diabetes, Florida Hospital and the Sanford Burnham Institute, Winter Park, FL 32789, USA
    N Engl J Med 363:245-56. 2010
  5. ncbi Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure
    Paul Mulder
    INSERM U644, , Rouen, France
    Circulation 109:1674-9. 2004
  6. ncbi Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women
    Steven R Smith
    Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA
    Obesity (Silver Spring) 17:494-503. 2009
  7. ncbi Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database
    D Gunnell
    University of Bristol, Department of Social Medicine, University of Bristol, Bristol BS8 2PS
    BMJ 339:b3805. 2009
  8. ncbi Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization
    William J Thomsen
    Arena Pharmaceuticals, Inc, 6166 Nancy Ridge Dr, San Diego, CA 92121, USA
    J Pharmacol Exp Ther 325:577-87. 2008
  9. ncbi Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial
    Nancy A Rigotti
    General Medicine Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Tobacco Research and Treatment Center, Boston, Mass 02114, USA
    Circulation 121:221-9. 2010
  10. ncbi The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system
    Mia Ericson
    Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    J Pharmacol Exp Ther 329:225-30. 2009

Research Grants

  1. Synthesis of Bioactive Complex Alkaloids
    DAVID GIN; Fiscal Year: 2006
  2. High Dose Nicotine Patch Therapy for Spit Tobacco Users
    Jon Ebbert; Fiscal Year: 2004
  3. Brief Dental Office Intervention with Tobacco Quitline
    Jon Ebbert; Fiscal Year: 2005
  4. Evaluating Nicoting Lozenges for Treatment of Smokeless Tobacco Addiction
    Jon Ebbert; Fiscal Year: 2007
  5. Evaluating Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
    Jon Ebbert; Fiscal Year: 2009
  6. Combination Therapy with Varenicline and Bupropion for Smoking Cessation
    Jon O Ebbert; Fiscal Year: 2010
  7. Polycystic Kidney Disease: Innovative Imaging to Assess Progression (PCC)
    Vicente Torres; Fiscal Year: 2007
  8. Novel treatments for polycystic kidney disease
    Vicente Torres; Fiscal Year: 2009
  9. CNS Mechanisms that Modulate Reward
    Kenneth D Carr; Fiscal Year: 2010
  10. REDOX, ACID/BASE, AND PATHOGENESIS OF ADPKD
    Vicente Torres; Fiscal Year: 2002

Detail Information

Publications204 found, 100 shown here

  1. ncbi Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling
    Gerard J O'Sullivan
    Molecular and Cellular Therapeutics and RCSI Research Institute, Royal College of Surgeons in Ireland, Dublin 2, Ireland
    Neuropharmacology 54:1051-61. 2008
    ..These findings indicate that D(1), and to a lesser extent D(5), receptor coupling to DARPP-32, ERK1/2 and glutamatergic signalling is involved in mediating the convulsant effects of SKF 83822...
  2. ncbi Varenicline reduces alcohol self-administration in heavy-drinking smokers
    Sherry A McKee
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
    Biol Psychiatry 66:185-90. 2009
    ..Varenicline, a partial nicotinic agonist with high affinity for the alpha4beta2 nAChR receptor, reduced ethanol intake in rodents. We aimed to test whether varenicline would reduce alcohol consumption and alcohol craving in humans...
  3. ncbi Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking
    Pia Steensland
    Ernest Gallo Clinic and Research Center, University of California, San Francisco, 5858 Horton Street, Suite 200, Emeryville, CA 94608, USA
    Proc Natl Acad Sci U S A 104:12518-23. 2007
    ..The selectivity of varenicline in decreasing ethanol consumption combined with its reported safety profile and mild side effects in humans suggest that varenicline may prove to be a treatment for alcohol dependence...
  4. ncbi Multicenter, placebo-controlled trial of lorcaserin for weight management
    Steven R Smith
    Translational Research Institute for Metabolism and Diabetes, Florida Hospital and the Sanford Burnham Institute, Winter Park, FL 32789, USA
    N Engl J Med 363:245-56. 2010
    ..Lorcaserin is a selective serotonin 2C receptor agonist that could be useful in reducing body weight...
  5. ncbi Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure
    Paul Mulder
    INSERM U644, , Rouen, France
    Circulation 109:1674-9. 2004
    ..The improvement of cardiac function is related not only to the HRR per se but also to modifications in the extracellular matrix and/or function of myocytes as a consequence of long-term HRR...
  6. ncbi Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women
    Steven R Smith
    Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA
    Obesity (Silver Spring) 17:494-503. 2009
    ..Lorcaserin was well tolerated and efficacious for weight reduction in this 12-week study. Longer-term trials employing behavior modification will be needed to more fully assess its safety and efficacy...
  7. ncbi Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database
    D Gunnell
    University of Bristol, Department of Social Medicine, University of Bristol, Bristol BS8 2PS
    BMJ 339:b3805. 2009
    ..To determine whether varenicline, a recently licensed smoking cessation product, is associated with an increased risk of suicide and suicidal behaviour compared with alternative treatments bupropion and nicotine replacement therapy...
  8. ncbi Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization
    William J Thomsen
    Arena Pharmaceuticals, Inc, 6166 Nancy Ridge Dr, San Diego, CA 92121, USA
    J Pharmacol Exp Ther 325:577-87. 2008
    ..Upon discontinuation, body weight returned to control levels. These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT(2C) receptor, with potential for the treatment of obesity...
  9. ncbi Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial
    Nancy A Rigotti
    General Medicine Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Tobacco Research and Treatment Center, Boston, Mass 02114, USA
    Circulation 121:221-9. 2010
    ..Varenicline, a partial alpha4beta2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown...
  10. ncbi The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system
    Mia Ericson
    Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    J Pharmacol Exp Ther 329:225-30. 2009
    ....
  11. ncbi Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition
    Hans Rollema
    Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    Biochem Pharmacol 78:813-24. 2009
    ....
  12. ncbi Adverse effects and tolerability of medications for the treatment of tobacco use and dependence
    J Taylor Hays
    Mayo Clinic Nicotine Dependence Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Drugs 70:2357-72. 2010
    ..Given these factors, the benefit : risk ratio is strongly in favour of pharmacotherapy for tobacco dependence treatment in virtually all smokers who are motivated to quit...
  13. ncbi Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice
    Danielle Gulick
    Department of Psychology, Neuroscience Program, Temple University, Weiss Hall, Rm 865, 1701 N 13th Street, Philadelphia, PA 19122, USA
    Neurobiol Learn Mem 90:230-6. 2008
    ..In addition, varenicline did not alter blood alcohol concentration. The smoking cessation aid varenicline may have therapeutic uses for treating ethanol-associated disruptions in cognitive processes...
  14. ncbi Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting
    Abigail C Halperin
    University of Washington, Seattle, 1107 NE 45th Street, Suite 345, Seattle, WA 98105, USA
    J Subst Abuse Treat 36:428-34. 2009
    ..21%, p < .01). Counseling may improve tolerance of this medication and reduce the rate of discontinuation due to side effects...
  15. ncbi Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist
    Serena Tonstad
    Department of Preventive Cardiology, Ulleval University Hospital, Oslo, Norway
    J Cardiovasc Nurs 21:433-6. 2006
    ..Phase 3 studies have evaluated the effects of varenicline on inducing smoking cessation and maintaining smoking abstinence...
  16. ncbi Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons
    Can Gao
    Department of Neuroscience, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064 3095, USA
    J Neurochem 106:2489-501. 2008
    ..Our results show that tyrosine phosphorylation plays an important role in the trafficking of NR2B-containing NMDA receptors in PFC neurons and the regulation of their trafficking by DA receptors...
  17. ncbi Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats
    Susmita Chatterjee
    Ernest Gallo Clinic and Research Center, University of California San Francisco, Emeryville, CA 94608, USA
    Neuropsychopharmacology 36:603-15. 2011
    ..CP-601932 has been shown to be safe in humans and may represent a potential novel treatment for AUDs...
  18. ncbi Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis
    Serena Tonstad
    Department of Preventive Cardiology, Oslo University Hospital Ulleval, Oslo, Norway
    Drug Saf 33:289-301. 2010
    ..In postmarketing surveillance, neuropsychiatric symptoms have appeared; however, their incidence and causal relationship to varenicline is not known...
  19. ncbi Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
    David Gonzales
    Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 296:47-55. 2006
    ..TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00141206...
  20. ncbi Distinct functions of the two isoforms of dopamine D2 receptors
    A Usiello
    Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS, INSERM, ULP, Illkirch, C U de Strasbourg, France
    Nature 408:199-203. 2000
    ..The absence of D2L reveals that D2S inhibits D1 receptor-mediated functions, uncovering a circuit of signalling interference between dopamine receptors...
  21. ncbi Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats
    Jeanette M Wood
    Novartis Institute for Biomedical Research, Basel, Switzerland
    J Hypertens 23:417-26. 2005
    ..Aliskiren may therefore represent an effective, novel approach to the treatment of hypertension and related disorders, alone or in combination with other antihypertensive agents...
  22. ncbi Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina
    Jean Claude Tardif
    Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada
    Eur Heart J 26:2529-36. 2005
    ..Ivabradine has shown anti-ischaemic and anti-anginal activity in a placebo-controlled trial. The objective of this study was to compare the anti-anginal and anti-ischaemic effects of ivabradine and the beta-blocker atenolol...
  23. ncbi Effectiveness of smoking cessation therapies: a systematic review and meta-analysis
    Ping Wu
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
    BMC Public Health 6:300. 2006
    ..These include Nicotine Replacement Therapy [NRT], bupropion, and varenicline. We aimed to assess their relative efficacy in smoking cessation by conducting a systematic review and meta-analysis...
  24. ncbi Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex
    Guojun Chen
    Department of Physiology and Biophysics, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY 14214, USA
    Proc Natl Acad Sci U S A 101:2596-600. 2004
    ..These interactions may play an important role in modulating synaptic plasticity and thus in cognitive and emotional processes...
  25. ncbi Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro
    R Scott Obach
    Department of Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA
    Drug Metab Dispos 34:121-30. 2006
    ..The straightforward dispositional profile of varenicline should simplify its use in the clinic as an aid in smoking cessation...
  26. ncbi Inhibition of cdk1 by alsterpaullone and thioflavopiridol correlates with increased transit time from mid G2 through prophase
    Deena V Soni
    Environmental Health Sciences Department, Case Western Reserve University, Cleveland, Ohio, USA
    Cell Cycle 3:349-57. 2004
    ..These results suggest that cdk1-cyclin activity is rate limiting for cell cycle progression during a period from mid G2 through prophase...
  27. ncbi Non-nicotinic therapies for smoking cessation
    Eric C K Siu
    Center for Addiction and Mental Health and Department of Pharmacology, University of Toronto, Toronto, Canada
    Annu Rev Pharmacol Toxicol 47:541-64. 2007
    ..In conclusion, promising new therapeutic products are emerging and they will provide smokers additional options to assist in achieving smoking cessation...
  28. ncbi Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial
    Witold Ruzyllo
    Department of Coronary Artery Disease and Cardiac Catheterization Laboratory, Institute of Cardiology, Warsaw, Poland
    Drugs 67:393-405. 2007
    ..This study was undertaken to compare the antianginal and anti-ischaemic effects of the novel heart-rate-lowering agent ivabradine and of the calcium channel antagonist amlodipine...
  29. ncbi Blockade of D1 dopaminergic transmission alleviates c-fos induction and cleaved caspase-3 expression in the brains of rat pups exposed to prenatal cocaine or perinatal asphyxia
    Ellen S Mitchell
    Department of Biomedical Sciences, State University at Albany, Albany, NY, USA
    Exp Neurol 182:64-74. 2003
    ..SCH 23390 decreased caspase-3 expression after both birth insults, indicating that the increased incidence of apoptosis is related to overactivation of dopaminergic pathways...
  30. ncbi Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues
    Niall P Hyland
    Centre for Neuroscience Research, King s College London, GKT School of Biomedical Sciences, Guy s Campus, London SE1 1UL, UK
    Br J Pharmacol 139:863-71. 2003
    ....
  31. ncbi Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise
    Robinson Joannides
    Department of Pharmacology, Rouen University Hospital, INSERM U644, Rouen, France
    Br J Clin Pharmacol 61:127-37. 2006
    ....
  32. ncbi Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels
    A Bucchi
    Laboratory of Molecular Physiology and Neurobiology, Department of Biomolecular Sciences and Biotechnology, University of Milano, Italy
    J Physiol 572:335-46. 2006
    ..The mode of action of ivabradine on the two channels is discussed by implementing a simplified version of a previously developed model of f-channel kinetics...
  33. ncbi The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline
    J Foulds
    Tobacco Dependence Program, UMDNJ School of Public Health, New Brunswick, NJ 08901, USA
    Int J Clin Pract 60:571-6. 2006
    ..Phase II and III trials have yielded promising results suggesting that varenicline could be an important advance in the treatment of nicotine dependence...
  34. ncbi Funny channels in the control of cardiac rhythm and mode of action of selective blockers
    Dario DiFrancesco
    University of Milano, Department of Biomolecular Sciences and Biotechnology, Laboratory of Molecular Physiology and Neurobiology, Via Celoria 26, 20133 Milano, Italy
    Pharmacol Res 53:399-406. 2006
    ..Finally, a channel mutation responsible for one type of a relatively common rhythm disturbance, sinus bradycardia, has been recently identified, highlighting the clinical relevance of funny channels in the pacemaker function...
  35. ncbi Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial
    Douglas E Jorenby
    University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, Madison, Wis 53711, USA
    JAMA 296:56-63. 2006
    ..Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine...
  36. ncbi Varenicline
    Raymond Niaura
    Nat Rev Drug Discov 5:537-8. 2006
  37. ncbi A double-blind study evaluating the long-term safety of varenicline for smoking cessation
    Kathryn E Williams
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Curr Med Res Opin 23:793-801. 2007
    ..We assessed the safety of long-term varenicline administration for smoking cessation...
  38. ncbi Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
    Jotham W Coe
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, USA
    J Med Chem 48:3474-7. 2005
    ..Varenicline displays high alpha4beta2 nAChR affinity and the desired in vivo dopaminergic profile...
  39. ncbi Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale
    Joseph C Cappelleri
    Pfizer Inc, Global Research and Development, Groton, CT 06340, USA
    Curr Med Res Opin 21:749-60. 2005
    ..No psychometric analyses of this version have been published. The objectives of this investigation were to perform a factor analysis and to further assess the psychometric properties of the MNWS...
  40. ncbi Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease
    Dario DiFrancesco
    Dipartimento di Scienze Biomolecolari e Biotecnologie, , Milan, Italy
    Drugs 64:1757-65. 2004
    ..Experimental data indicate a potential role of pure heart rate lowering in other cardiovascular conditions, such as heart failure...
  41. ncbi Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers
    Aaron H Burstein
    Department of Medical and Developmental Sciences, Pfizer Global Research and Development, Groton/New London Labs, MS8260-2505, Groton, CT 06340, USA
    J Clin Pharmacol 46:1234-40. 2006
    ..Varenicline was well tolerated; all adverse events reported were mild to moderate in intensity. Thus, no dose adjustment is necessary based on age alone...
  42. ncbi Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers
    Hélène M Faessel
    Department of Clinical Pharmacokinetics and Pharmacodynamics, Pfizer Global Research and Development, Eastern Point Road MS 8260 2309, Groton, CT 06340, USA
    J Clin Pharmacol 46:1439-48. 2006
    ..There was no evidence of concentration- or time-dependent changes in the pharmacokinetics of varenicline upon repeat dosing...
  43. ncbi An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation
    Kenneth C Jackson
    Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT 84108, USA
    J Occup Environ Med 49:453-60. 2007
    ..An employer-based cost-benefit analysis for varenicline versus bupropion was conducted using clinical outcomes from a recently published trial...
  44. ncbi Activation of the 5-HT1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393
    C A Briggs
    Department of Neuroscience, Abbot Laboratories, Abbott Park, Illinois 60064
    Br J Pharmacol 104:1038-44. 1991
    ..receptor expressed in Xenopus laevis oocytes was used to characterize the action of four dopamine D1-selective benzazepines at the 5-HT1C receptor...
  45. ncbi A preliminary benefit-risk assessment of varenicline in smoking cessation
    Kate Cahill
    Cochrane Tobacco Addiction Group, Department of Primary Health Care, Oxford University, Oxford, UK
    Drug Saf 32:119-35. 2009
    ....
  46. ncbi Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis
    Mitchell Nides
    Los Angeles Clinical Trials, 4116 W Magnolia Boulevard, Burbank, CA 91505, USA
    Am J Health Behav 32:664-75. 2008
    ....
  47. ncbi Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment
    Peter Hajek
    Wolfson Institute of Preventive Medicine, UK Centre for Tobacco Control Studies, Barts and The London, Queen Mary University of London, London E1 2AD, UK
    Addiction 104:1597-602. 2009
    ..In this secondary analysis, trial data were examined to see whether smokers who manage to achieve abstinence only later in the original course of treatment are more likely to benefit from having the course extended...
  48. ncbi Mediation of hippocampal mossy fiber long-term potentiation by presynaptic Ih channels
    Jack Mellor
    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94143, USA
    Science 295:143-7. 2002
    ..Thus, Ih channels play an important role in the long-lasting control of transmitter release and neuronal excitability...
  49. ncbi Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial
    H J Aubin
    Hôpital Emile Roux, Assistance Publique Hopitaux de Paris, Limeil Brevannes, Paris, France
    Thorax 63:717-24. 2008
    ..A study was undertaken to compare a 12-week standard regimen of varenicline with a 10-week standard regimen of transdermal nicotine replacement therapy (NRT) for smoking cessation...
  50. ncbi Hypomania with agitation associated with varenicline use in bipolar II disorder
    Anne E Morstad
    Ann Pharmacother 42:288-9. 2008
  51. ncbi Varenicline treatment for smokers with schizophrenia: a case series
    A Eden Evins
    J Clin Psychiatry 69:1016. 2008
  52. ncbi Treatment of tobacco dependence: integrating recent progress into practice
    Bernard Le Foll
    Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ont
    CMAJ 177:1373-80. 2007
    ..Specifically, we discuss the use of nicotine replacement therapy, bupropion and varenicline in primary care settings...
  53. ncbi Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression
    Pejman Pirmoradi
    Medical City Dallas Hospital, Dallas, TX 75230, USA
    Am J Health Syst Pharm 65:1624-6. 2008
    ..The case of a patient with a history of alcohol abuse and major depression who developed neuropsychiatric symptoms after initiation of varenicline is reported...
  54. ncbi Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
    D W Zaharevitz
    Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892 7444, USA
    Cancer Res 59:2566-9. 1999
    ..Cells exposed to kenpaullone and 10-bromopaullone display delayed cell cycle progression. Kenpaullone represents a novel chemotype for compounds that preferentially inhibit CDKs...
  55. ncbi Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers
    Masakazu Nakamura
    Department of Health Promotion and Education, Osaka Medical Center for Health Science and Promotion, Osaka, Japan
    Clin Ther 29:1040-56. 2007
    ..Varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, has been developed specifically for smoking cessation. In Japan, 39.3% of men smoke and this is a major public health concern...
  56. ncbi Predictors of post-treatment relapse to smoking in successful quitters: pooled data from two phase III varenicline trials
    Jaimee L Heffner
    Tri State Tobacco and Alcohol Research Center, University of Cincinnati Genome Research Institute, 2120 E Galbraith Rd, Bldg A, Cincinnati, OH 45237, USA
    Drug Alcohol Depend 109:120-5. 2010
    ..Identifying predictors of smoking relapse helps to elucidate the challenges of long-term smoking cessation and provides direction for improved treatment development...
  57. ncbi Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49
    C Thollon
    Division Pathologies Cardiaques et Vasculaires, Institut de Recherches Servier, Suresnes, France
    Br J Pharmacol 112:37-42. 1994
    ..S 16257 and UL-FS 49 are equipotent in their bradycardic effect but S 16257 is more specific as it induces less increase in myocardial repolarization time...
  58. ncbi Varenicline-induced manic episode in a patient with bipolar disorder
    Izchak Kohen
    Am J Psychiatry 164:1269-70. 2007
  59. ncbi Evidence for the sensitivity of operant timing behaviour to stimulation of D1 dopamine receptors
    T H C Cheung
    Psychopharmacology Section, Division of Psychiatry, University of Nottingham, Room B109, Medical School, Queen s Medical Centre, Nottingham, NG7 2UH, UK
    Psychopharmacology (Berl) 195:213-22. 2007
    ..It is not known whether this effect of d-amphetamine is mimicked by direct D(1)-like receptor stimulation...
  60. ncbi Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor
    Frank J S Lee
    Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, University of Toronto, Toronto, M5T 1R8, Ontario, Canada
    Cell 111:219-30. 2002
    ..While one interaction is involved in the inhibition of NMDA receptor-gated currents, the other is implicated in the attenuation of NMDA receptor-mediated excitotoxicity through a PI-3 kinase-dependent pathway...
  61. ncbi Thoughts and acts of aggression/violence toward others reported in association with varenicline
    Thomas J Moore
    Institute for Safe Medication Practices, Horsham, PA, USA
    Ann Pharmacother 44:1389-94. 2010
    ..Thoughts and acts of aggression/violence toward others have been reported in postmarketing surveillance of varenicline, an aid to smoking cessation...
  62. ncbi Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice
    Florian Custodis
    Klinik fur Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, 66424 Homburg Saar, Germany
    Circulation 117:2377-87. 2008
    ..We hypothesized that selective heart rate reduction may influence endothelial function and atherogenesis and tested the effects of the I(f) current inhibitor ivabradine in apolipoprotein E-deficient mice...
  63. ncbi Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D(1)-like receptors: studies with SK&F 83822
    Satoshi Fujita
    Department of Pharmacology, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo 101-8310, Japan
    Eur J Pharmacol 538:94-100. 2006
    ....
  64. ncbi Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats
    M Carta
    Department of Applied Science for Biosystems, Section of Nutrition and Human Physiology, University of Cagliari, Italy
    Neuroscience 139:1163-72. 2006
    ..Our results stress the basic role of vitamin A in the maintenance of basal ganglia motor function in the adult rat brain...
  65. ncbi D1 or D2 antagonism in nucleus accumbens core or dorsomedial shell suppresses lever pressing for food but leads to compensatory increases in chow consumption
    K L Nowend
    Unit 1020, Department of Psychology, University of Connecticut, 406 Babbidge Road, Storrs, CT 06269-1020, USA
    Pharmacol Biochem Behav 69:373-82. 2001
    ..Nevertheless, interference with accumbens DA does appear to set constraints upon which responses are selected for obtaining food, and may impair the ability of animals to overcome work-related response costs in order to obtain food...
  66. ncbi Comparison of basal and D-1 dopamine receptor agonist-stimulated neuropeptide gene expression in caudate-putamen and nucleus accumbens of ad libitum fed and food-restricted rats
    Sandra L Haberny
    Department of Pharmacology, Millhauser Laboratories, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Brain Res Mol Brain Res 141:121-7. 2005
    ....
  67. ncbi Receptor recycling mediates plasma membrane recovery of dopamine D1 receptors in dendrites and axons after agonist-induced endocytosis in primary cultures of striatal neurons
    Marie Laure Martin-Negrier
    CNRS UMR 5541, Université V Segalen Bordeaux 2, Laboratoire d Histologie Embryologie, Bordeaux Cedex, France
    Synapse 60:194-204. 2006
    ..Temporal characteristics observed for the recovery of D1R density to the basal state and those observed for the resensitization process strongly suggest that D1R recycling supports the receptor resensitization...
  68. ncbi Behavioral and molecular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal
    Elena H Chartoff
    Behavioral Genetics Laboratory, Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02478, USA
    J Neurosci 26:6450-7. 2006
    ..Regardless, these findings suggest for the first time that D1 agonists might be useful for the treatment of withdrawal symptoms that contribute to the maintenance of opiate addiction in humans...
  69. ncbi Dopamine D1 receptor activation regulates sodium channel-dependent EPSP amplification in rat prefrontal cortex pyramidal neurons
    Diana C Rotaru
    Translational Neuroscience Program, Department of Psychiatry, University of Pittsburgh School of Medicine, W1651 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15261, USA
    J Physiol 581:981-1000. 2007
    ..Therefore, the effects of D1R activation on Na+ channel-dependent EPSP amplification may regulate the impact of coincidence detection versus temporal integration mechanisms in PFC pyramidal neurons...
  70. ncbi Role of dopamine D1 and D2 receptors in the nucleus accumbens shell on the acquisition and expression of fructose-conditioned flavor-flavor preferences in rats
    Sonia Y Bernal
    Neuropsychology Doctoral Subprogram, Graduate Center, City University of New York, New York, NY, USA
    Behav Brain Res 190:59-66. 2008
    ..These data indicate that NAcS D1 and D2 antagonists significantly attenuated the expression of the fructose-CFP and did not block acquisition, but hastened extinction of fructose-CFP...
  71. ncbi D1-like dopamine receptors selectively block P/Q-type calcium channels to reduce glutamate release onto cholinergic basal forebrain neurones of immature rats
    Toshihiko Momiyama
    Division of Cerebral Structure, National Institute for Physiological Sciences, Okazaki 444 8787, Japan
    J Physiol 580:103-17. 2007
    ..These results suggest that D(1)-like receptor activation selectively blocks P/Q-type calcium channels to reduce glutamate release onto BF cholinergic neurones...
  72. ncbi Dopamine receptors in the anterior insular cortex modulate long-term nociception in the rat
    Ulises Coffeen
    Laboratorio de Neurofisiología Integrativa, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de Fuente, Camino a Xochimilco 101, San Lorenzo Huipulco, Tlalpan, México D F CP 14370, Mexico
    Eur J Pain 12:535-43. 2008
    ..This work shows the differential role of dopamine receptors within the RAIC in which the activation of D(2) or the blockade of D(1) receptors elicit antinociception...
  73. ncbi Pharmacological characterization of the effects of dopamine D(1) agonists on eye blinking in rats
    Rajeev I Desai
    Preclinical Pharmacology Laboratory, McLean Hospital Harvard Medical School, Belmont, Massachusetts 02478, USA
    Behav Pharmacol 18:745-54. 2007
    ..Further studies with novel D(1)-like partial agonists may be useful in the development of pharmacotherapies for cocaine abuse...
  74. ncbi Dopamine D2 receptor-dependent modulation of striatal NO synthase activity
    Stephen Sammut
    Department of Neuroscience, The Chicago Medical School at Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL, 60064, USA
    Psychopharmacology (Berl) 191:793-803. 2007
    ....
  75. ncbi Motor-skill learning in a novel running-wheel task is dependent on D1 dopamine receptors in the striatum
    I Willuhn
    Department of Cellular and Molecular Pharmacology, Rosalind Franklin University of Medicine and Science The Chicago Medical School, 3333 Green Bay Road, North Chicago, IL 60064, USA
    Neuroscience 153:249-58. 2008
    ..Furthermore, our findings demonstrate that D1 receptors in the striatum are critical for consolidation of long-term skill memory...
  76. ncbi Effects of dopamine D1-like receptor agonists on food-maintained operant behavior in rats
    Jonathan L Katz
    Psychobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, USA
    Behav Pharmacol 17:303-9. 2006
    ....
  77. ncbi Dopamine D1 receptor-dependent regulation of extracellular citrulline level in the rat nucleus accumbens during conditioned fear response
    Natalia B Saulskaya
    Laboratory of Higher Nervous Activity, I P Pavlov Institute of Physiology, Russian Academy of Sciences, 6 Admiral Makarov Embankment, St Petersburg 199034, Russia
    Neurosci Lett 440:185-9. 2008
    ....
  78. ncbi Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons
    Christian O Alberto
    Division of Basic Medical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada A1B 3V6
    J Neurosci 26:10043-50. 2006
    ..In conclusion, our results suggest that D1- and D2-like receptors have opposing effects on the excitatory presynaptic terminals impinging onto orexin neurons...
  79. ncbi The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats
    David Wirtshafter
    Laboratory of Integrative Neuroscience, Department of Psychology, M C 285, University of Illinois at Chicago, 1007 W Harrison St, Chicago, IL 60607 7137, USA
    Eur J Pharmacol 528:88-94. 2005
    ....
  80. ncbi Differential actions of dopamine receptor antagonism in rats upon food intake elicited by either mercaptoacetate or exposure to a palatable high-fat diet
    R W Baker
    Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, 65-30 Kissena Boulevard, Flushing, NY 11367, USA
    Pharmacol Biochem Behav 69:201-8. 2001
    ....
  81. ncbi Effects of individual and concurrent stimulation of striatal D1 and D2 dopamine receptors on electrophysiological and behavioral output from rat basal ganglia
    Barbara L Waszczak
    Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA
    J Pharmacol Exp Ther 300:850-61. 2002
    ....
  82. ncbi Comparison of interactions of D1-like agonists, SKF 81297, SKF 82958 and A-77636, with cocaine: locomotor activity and drug discrimination studies in rodents
    Allison L Chausmer
    Medications Discovery Research Branch, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 159:145-53. 2002
    ..Because A-77636 consistently attenuated the present effects of cocaine, it may prove more useful than the others as a pharmacotherapy to treat cocaine abuse...
  83. ncbi Blockade or stimulation of D1 dopamine receptors attenuates cue reinstatement of extinguished cocaine-seeking behavior in rats
    Andrea T Alleweireldt
    Department of Psychology, Arizona State University, Box 871104, Tempe, AZ 85287-1104, USA
    Psychopharmacology (Berl) 159:284-93. 2002
    ..CONCLUSIONS: While the antagonist and full agonist produced similar effects on cocaine-seeking behavior, only the agonist increased response latency, suggesting that different processes mediate the effects of these drugs...
  84. ncbi No change in dopamine D1 receptor in vivo binding in rats after sub-chronic haloperidol treatment
    Vito Sanci
    PET Centre, Centre for Addiction and Mental Health, University of Toronto, ON, Canada
    Can J Physiol Pharmacol 80:36-41. 2002
    ..This study failed to link the purported D1 receptor-mediated behaviors with in vivo receptor binding measures of R-[11C]SKF 82957 or [11C]SCH 23390 in rat brain regions...
  85. ncbi Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition
    Mareo Naitoh
    Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia
    Cardiovasc Res 54:51-7. 2002
    ..These results suggest conivaptan may be a useful addition to ACE inhibitors in the management of vasoconstriction and fluid retention that characterizes CHF...
  86. ncbi Striatal preprotachykinin mRNA levels are regulated by stimulatory agents and dopamine D1 receptor manipulation in rodent organotypic slice cultures
    B M Campbell
    Cellular and Clinical Neurobiology Program, Department of Psychiatry and Behavioral Neurosciences, Wayne State University, School of Medicine, Detroit, MI 48201, USA
    Brain Res 888:26-33. 2001
    ..5+/-5.4%). These findings indicate that tachykinin gene expression is inducible within slice culture preparations and that the maintenance of normal striatal PPT mRNA levels depends on DA D1 receptor tone...
  87. ncbi Injection of SCH 23390, but not 7-hydroxy-DPAT, into the ventral tegmental area blocks the acute motor-stimulant response to cocaine
    J D Steketee
    Department of Pharmacology and Therapeutics, Louisiana State University Medical Center at Shreveport 71130 3932, USA
    Behav Pharmacol 8:58-64. 1997
    ..These data suggest that DA D1 receptors in the VTA may play a role in psychostimulant-induced motor activity. However, the role DA D2/3 receptors in the VTA may have in cocaine-induced motor activity remains unclear...
  88. ncbi D(1) dopamine receptor stimulation increases GluR1 phosphorylation in postnatal nucleus accumbens cultures
    Steven Z Chao
    Department of Neuroscience, FUHS/The Chicago Medical School, North Chicago, Illinois 60064-3095, USA
    J Neurochem 81:984-92. 2002
    ..Thus, the present results suggest that AMPA receptor transmission in the nucleus accumbens may be augmented by concurrent D(1) receptor stimulation...
  89. ncbi Concurrent activation of dopamine D1 and D2 receptors is required to evoke neural and behavioral phenotypes of cocaine sensitization
    Christine Capper-Loup
    Department of Neurology, University Hospital, 3010 Bern, Switzerland
    J Neurosci 22:6218-27. 2002
    ....
  90. ncbi D1 dopamine receptor stimulation increases GluR1 surface expression in nucleus accumbens neurons
    Steven Z Chao
    Department of Neuroscience, The Chicago Medical School, 3333 Green Bay Road, North Chicago, IL 60064-3095, USA
    J Neurochem 83:704-12. 2002
    ..When dopamine receptors are over-stimulated during chronic drug administration, this regulation may be disrupted, leading to inappropriate plasticity in neuronal circuits governing motivation and reward...
  91. ncbi SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals?
    A R Cools
    Department of Psychoneuropharmacology, Nijmegen Institute of Neurosciences, University of Nijmegen, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Neuropharmacology 42:237-45. 2002
    ..The role of these receptors in the antiparkinson profile of SKF 83959 is discussed...
  92. ncbi Intrastriatal GABA(A) receptor blockade does not alter dopamine D(1)/D(2) receptor interactions in the intact rat striatum
    E A Jones
    Department of Anatomy and Cell Biology, East Carolina University, School of Medicine, Greenville, NC 27858, USA
    Neuroscience 102:381-9. 2001
    ..These data indicate that blockade of striatal GABA(A) receptors has only a subtle effect on acute dopamine agonist-induced changes in gene expression. These results are discussed in the context of local intrastriatal interactions...
  93. ncbi Decreased striatal dopamine efflux after intrastriatal application of benzazepine-class D1 agonists is not mediated via dopamine receptors
    J A Zackheim
    Center for Molecular and Behavioral Neuroscience, Rutgers University, Newark, NJ 07102, USA
    Brain Res Bull 54:603-7. 2001
    ..There is therefore no indication for an intrastriatal population of D1 receptors capable of modulating dopamine efflux...
  94. ncbi Substantia nigra pars reticulata is a highly potent site of action for the behavioral effects of the D1 antagonist SCH 23390 in the rat
    J T Trevitt
    Department of Psychology, University of Connecticut, Storrs 06269-1020, USA
    Psychopharmacology (Berl) 156:32-41. 2001
    ..It is possible that blockade of SNr D1 receptors modulates GABA release from striatonigral neurons...
  95. ncbi Stimulation of D1-type dopamine receptors enhances excitability in prefrontal cortical pyramidal neurons in a state-dependent manner
    A Lavin
    Department of Neuroscience, University of Pittsburgh, 446 Crawford Hall, Pittsburgh, PA 15260, USA
    Neuroscience 104:335-46. 2001
    ..From these data we suggest that dopamine exerts state-dependent modulatory effects on the excitability of neurons in deep layers of the prefrontal cortex...
  96. ncbi Ventral striatal vs. accumbal (shell) mechanisms and non-cyclase-coupled dopamine D(1)-like receptors in jaw movements
    M Hasegawa
    Department of Pharmacology, Nihon University School of Dentistry, 1-8-13 Kanda-Surugadai, Chiyoda, Tokyo 101-8310, Japan
    Eur J Pharmacol 423:171-8. 2001
    ....
  97. ncbi Intrapallidal dopamine restores motor deficits induced by 6-hydroxydopamine in the rat
    A Galvan
    , , , ,
    J Neural Transm 108:153-66. 2001
    ..Moreover, motor recovery was produced by selectively injecting dopamine into the globus pallidus...
  98. ncbi The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors
    M J Millan
    Institut de Recherches Servier, Psychopharmacology Department, Paris, France
    Psychopharmacology (Berl) 156:58-62. 2001
    ..57 nM. CONCLUSIONS: SCH23390 is a potent and high efficacy agonist at h5-HT2C receptors. Activation of 5-HT2C receptors by SCH23390 may contribute to its functional properties both in animals and in humans...
  99. ncbi Influence of glucocorticoids on dopaminergic transmission in the rat dorsolateral striatum
    M Barrot
    Psychobiologie des Comportements Adaptatifs, INSERM U259, , , 33077 Bordeaux Cedex, France
    Eur J Neurosci 13:812-8. 2001
    ..2000) Eur. J. Neurosci., 12, 973-979]. The present data highlight the profound heterogeneous influence of glucocorticoids within dopaminergic projections...
  100. ncbi Stimulated D(1) dopamine receptors couple to multiple Galpha proteins in different brain regions
    L Q Jin
    Laboratory of Molecular Pharmacology, Department of Pharmacology and Physiology, MCP Hahnemann School of Medicine, Philadelphia 19102, USA
    J Neurochem 78:981-90. 2001
    ..The results indicate that in addition to the D(1)/G(s)/adenylyl cyclase system, brain D(1)-like dopamine receptor sites activate phospholipase C through Galpha(q) protein...
  101. ncbi Stimulatory role of dopamine on fibroblast growth factor-2 expression in rat striatum
    M Roceri
    Centre for Neuropharmacology, Department of Pharmacological Sciences, University of Milan, Milan, Italy
    J Neurochem 76:990-7. 2001
    ..On the basis of FGF-2 neurotrophic activity, these results suggest that direct or indirect activation of dopaminergic system can be neuroprotective and might reduce cell vulnerability in degenerative disorders...

Research Grants120 found, 100 shown here

  1. Synthesis of Bioactive Complex Alkaloids
    DAVID GIN; Fiscal Year: 2006
    ..pyrrolidines, as well as strain-accelerated [3,3]-sigmatropic rearrangement for the synthesis of complex benzazepines. Successful synthesis of these target molecules will not only lay the foundation for efficient and practical ..
  2. High Dose Nicotine Patch Therapy for Spit Tobacco Users
    Jon Ebbert; Fiscal Year: 2004
    ..Our goal is to reduce the prevalence of ST use and decrease the incidence of oropharyngeal cancer through the development of effective treatment options for ST users. ..
  3. Brief Dental Office Intervention with Tobacco Quitline
    Jon Ebbert; Fiscal Year: 2005
    ..S. adult population smoking; and 3) 75% of smokers quitting for at least one day or longer because they are trying to quit. ..
  4. Evaluating Nicoting Lozenges for Treatment of Smokeless Tobacco Addiction
    Jon Ebbert; Fiscal Year: 2007
    ..No drug therapies have been shown to be effective for helping smokeless tobacco users quit for good. The purpose of this study is to test drugs that can be used to help smokeless tobacco users quit for good. ..
  5. Evaluating Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
    Jon Ebbert; Fiscal Year: 2009
    ..No drug therapies have been shown to be effective for helping smokeless tobacco users quit for good. The purpose of this study is to test drugs that can be used to help smokeless tobacco users quit for good. ..
  6. Combination Therapy with Varenicline and Bupropion for Smoking Cessation
    Jon O Ebbert; Fiscal Year: 2010
    ..Combining medications together may increase the long-term smoking quit rates and decrease the death and disability associated with cigarette smoking. ..
  7. Polycystic Kidney Disease: Innovative Imaging to Assess Progression (PCC)
    Vicente Torres; Fiscal Year: 2007
    ....
  8. Novel treatments for polycystic kidney disease
    Vicente Torres; Fiscal Year: 2009
    ..abstract_text> ..
  9. CNS Mechanisms that Modulate Reward
    Kenneth D Carr; Fiscal Year: 2010
    ....
  10. REDOX, ACID/BASE, AND PATHOGENESIS OF ADPKD
    Vicente Torres; Fiscal Year: 2002
    ..The main thrust of the proposed studies is directed towards the identification of pathogenetic mechanisms than can be subject to preventive and therapeutic interventions. ..
  11. Novel treatment for polycystic kidney disease
    Vicente E Torres; Fiscal Year: 2010
    ....
  12. Novel treatments for polycystic kidney disease
    Vicente Torres; Fiscal Year: 2007
    ....
  13. CNS Mechanisms that Modulate Reward
    KENNETH CARR; Fiscal Year: 2007
    ....
  14. KIDNEY DISEASE RESEARCH TRAINING PROGRAM
    Vicente Torres; Fiscal Year: 2007
    ..abstract_text> ..
  15. OPIOID MECHANISMS THAT FACILITATE REWARD
    KENNETH CARR; Fiscal Year: 2006
    ..abstract_text> ..
  16. Controlled Trial of Renin Angiotensin Blockade in ADPKD
    Vicente Torres; Fiscal Year: 2007
    ..Approximately one-half of these patients will have normal or near-normal renal function and one-half have mild to moderate renal insufficiency. The protocols for the Pilot Study will be conducted only at the Mayo Clinic. ..
  17. AASK Cohort Study
    Kenneth Jamerson; Fiscal Year: 2007
    ..Ultimately, data from the AASK Cohort Study should enhance our understanding of the determine the progression of kidney disease. Such results might eventually lead to new ESRD. ..
  18. CNS OPIOID MECHANISMS THAT MODULATE REWARD AND AVERSION
    KENNETH CARR; Fiscal Year: 2002
    ....
  19. RENIN ANGIOTENSIN SYSTEM IN THE PATHOGENESIS OF ADPKD
    Vicente Torres; Fiscal Year: 1993
    ..The results of these studies will augment the understanding of the pathogenesis of cyst formation and hypertension in ADPKD and are likely to have a significant impact on the treatment of this disease...
  20. CHRONIC AND ACUTE TOLERANCE TO NICOTINE IN HUMANS
    Kenneth Perkins; Fiscal Year: 1999
    ....
  21. Step Up Wellness Program for Depression Physical Inactivity and Smoking
    JENNIFER MC CLURE; Fiscal Year: 2007
    ..This work will provide valuable information about the feasibility, acceptability, and impact of this comprehensive treatment approach and will lay the ground work for future research in this area. ..
  22. Optimizing an online motivational tobacco cessation program
    JENNIFER B MC CLURE; Fiscal Year: 2010
    ..Information learned from this study will advance the science of tailoring health risk communications, as well as inform how to best design an online motivational intervention for smoking cessation. ..
  23. Tobacco Smoking, Nicotine and Negative Affect Relief
    Kenneth Perkins; Fiscal Year: 2009
    ..In sum, this research will help address the fundamental question of why cigarette smoking is reinforcing. ..
  24. Tobacco Smoking, Nicotine and Negative Affect Relief
    Kenneth Perkins; Fiscal Year: 2007
    ..In sum, this research will help address the fundamental question of why cigarette smoking is reinforcing. ..
  25. Proactive Cessation Intervention with Biomarker Feedback
    JENNIFER MC CLURE; Fiscal Year: 2007
    ..If effective, this treatment strategy could have broad potential as a public health intervention. ..
  26. SEX DIFFERENCES IN NICOTINE REINFORCEMENT: HUMAN/ANIMAL
    Kenneth Perkins; Fiscal Year: 2003
    ....
  27. INDIVIDUAL VARIATION IN NICOTINE SENSITIVITY IN HUMANS
    Kenneth Perkins; Fiscal Year: 2003
    ..e., in nicotine-naive individuals). Results will provide directions for future research on vulnerability to tobacco dependence and for targeted efforts to prevent smoking onset. ..
  28. DISCRIMINATIVE STIMULUS EFFECTS OF NICOTINE
    Kenneth Perkins; Fiscal Year: 2001
    ....
  29. CHRONIC AND ACUTE TOLERANCE TO NICOTINE IN HUMANS
    Kenneth Perkins; Fiscal Year: 1993
    ..Results may proivde directions for the study of mechanisms responsible for tolerance, as well as for investigations of physiological and behavioral aspects of nicotine depenence and smoking relapse...
  30. Affect, Context, and Placebo Responses to Nicotine
    Kenneth Perkins; Fiscal Year: 2005
    ..Secondary analyses may identify important individual characteristics associated with placebo responses, aiding in the prediction of which smokers ultimately are likely to benefit most from manipulation of placebo effects. ..
  31. ASK, ADVISE, REFER: Promoting Pharmacy-based Referrals to Tobacco Quitlines
    Karen Hudmon; Fiscal Year: 2009
    ....
  32. Safety of Nicotine Reduction Strategy
    Neal Benowitz; Fiscal Year: 2009
    ..The proposed research is needed to guide governmental regulators as to how best to regulate nicotine in cigarettes and is an essential first step in examining the feasibility of a national regulation program. ..